Phaseline

Companies › Amivas

Amivas: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Infectious disease, Oncology; next expected readout May 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Artesunate
Antimalarial artemisinin derivative with antiviral properties against CMV
–Phase 2CMV Infection; Chronic Myeloid Leukemia (CML)May 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07022743ArtesunatePhase 2Chronic Myeloid Leukemia (CML)OncologyJun 2027
NCT06853184ArtesunatePhase 2CMV InfectionInfectious diseaseMay 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Tetraphase Pharmaceuticals Cantex Pharmaceuticals The Skin Center Dermatology Group NanoEcho Syncromune

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.